BACKGROUND: The effect of timing of exposure to first Plasmodium falciparum infections during early childhood on the induction of innate and adaptive cytokine responses and their contribution to the development of clinical malaria immunity is not well established. METHODS: As part of a double-blind, randomized, placebo-controlled trial in Mozambique using monthly chemoprophylaxis with sulfadoxine-pyrimethamine plus artesunate to selectively control timing of malaria exposure during infancy, peripheral blood mononuclear cells collected from participants at age 2.5, 5.5, 10.5, 15, and 24 months were stimulated ex vivo with parasite schizont and erythrocyte lysates. Cytokine messenger RNA expressed in cell pellets and proteins secreted in supernatants were quantified by reverse-transcription quantitative polymerase chain reaction and multiplex flow cytometry, respectively. Children were followed up for clinical malaria from birth until 4 years of age. RESULTS:Higher proinflammatory (interleukin [IL] 1, IL-6, tumor necrosis factor) and regulatory (IL-10) cytokine concentrations during the second year of life were associated with reduced incidence of clinical malaria up to 4 years of age, adjusting by chemoprophylaxis and prior malaria exposure. Significantly lower concentrations of antigen-specific T-helper 1 (IL-2, IL-12, interferon-γ) and T-helper 2 (IL-4, IL-5) cytokines by 2 years of age were measured in children undergoing chemoprophylaxis compared to children receiving placebo (P < .03). CONCLUSIONS: Selective chemoprophylaxis altering early natural exposure to malaria blood stage antigens during infancy had a significant effect on T-helper lymphocyte cytokine production >1 year later. Importantly, a balanced proinflammatory and anti-inflammatory cytokine signature, probably by innate cells, around age 2 years was associated with protective clinical immunity during childhood. CLINICAL TRIALS REGISTRATION: NCT00231452.
RCT Entities:
BACKGROUND: The effect of timing of exposure to first Plasmodium falciparum infections during early childhood on the induction of innate and adaptive cytokine responses and their contribution to the development of clinical malaria immunity is not well established. METHODS: As part of a double-blind, randomized, placebo-controlled trial in Mozambique using monthly chemoprophylaxis with sulfadoxine-pyrimethamine plus artesunate to selectively control timing of malaria exposure during infancy, peripheral blood mononuclear cells collected from participants at age 2.5, 5.5, 10.5, 15, and 24 months were stimulated ex vivo with parasite schizont and erythrocyte lysates. Cytokine messenger RNA expressed in cell pellets and proteins secreted in supernatants were quantified by reverse-transcription quantitative polymerase chain reaction and multiplex flow cytometry, respectively. Children were followed up for clinical malaria from birth until 4 years of age. RESULTS: Higher proinflammatory (interleukin [IL] 1, IL-6, tumor necrosis factor) and regulatory (IL-10) cytokine concentrations during the second year of life were associated with reduced incidence of clinical malaria up to 4 years of age, adjusting by chemoprophylaxis and prior malaria exposure. Significantly lower concentrations of antigen-specific T-helper 1 (IL-2, IL-12, interferon-γ) and T-helper 2 (IL-4, IL-5) cytokines by 2 years of age were measured in children undergoing chemoprophylaxis compared to children receiving placebo (P < .03). CONCLUSIONS: Selective chemoprophylaxis altering early natural exposure to malaria blood stage antigens during infancy had a significant effect on T-helper lymphocyte cytokine production >1 year later. Importantly, a balanced proinflammatory and anti-inflammatory cytokine signature, probably by innate cells, around age 2 years was associated with protective clinical immunity during childhood. CLINICAL TRIALS REGISTRATION: NCT00231452.
Authors: Jennifer F Friedman; Penelope A Phillips-Howard; William A Hawley; Dianne J Terlouw; Margarette S Kolczak; Marlene Barber; Norman Okello; John M Vulule; Christopher Duggan; Bernard L Nahlen; Feiko O ter Kuile Journal: Am J Trop Med Hyg Date: 2003-04 Impact factor: 2.345
Authors: Francisco Saúte; John Aponte; Jesus Almeda; Carlos Ascaso; Rosa Abellana; Neide Vaz; Martinho Dgedge; Pedro Alonso Journal: Trans R Soc Trop Med Hyg Date: 2003 Nov-Dec Impact factor: 2.184
Authors: Amir Horowitz; Kirsty C Newman; J Henry Evans; Daniel S Korbel; Daniel M Davis; Eleanor M Riley Journal: J Immunol Date: 2010-04-28 Impact factor: 5.422
Authors: Matthew B B McCall; Mihai G Netea; Cornelus C Hermsen; Trees Jansen; Liesbeth Jacobs; Douglas Golenbock; André J A M van der Ven; Robert W Sauerwein Journal: J Immunol Date: 2007-07-01 Impact factor: 5.422
Authors: Louis Schofield; Lisa J Ioannidis; Stephan Karl; Leanne J Robinson; Qiao Y Tan; Daniel P Poole; Inoni Betuela; Danika L Hill; Peter M Siba; Diana S Hansen; Ivo Mueller; Emily M Eriksson Journal: BMC Med Date: 2017-06-15 Impact factor: 8.775
Authors: Berenger Kaboré; Annelies Post; Mike L T Berendsen; Salou Diallo; Palpouguini Lompo; Karim Derra; Eli Rouamba; Jan Jacobs; Halidou Tinto; Quirijn de Mast; Andre J van der Ven Journal: PLoS One Date: 2020-11-30 Impact factor: 3.240
Authors: Annelies Post; Berenger Kaboré; Mike Berendsen; Salou Diallo; Ousmane Traore; Rob J W Arts; Mihai G Netea; Leo A B Joosten; Halidou Tinto; Jan Jacobs; Quirijn de Mast; André van der Ven Journal: Front Immunol Date: 2021-06-09 Impact factor: 7.561